Table 2.
Association of pre-treatment antibody status with case-control status
| Cases N=256 |
Controls N=250 |
Pb | Crude OR (95% CI) |
Adjusted ORc (95% CI) |
|
|---|---|---|---|---|---|
| No. + (%) | No. + (%) | ||||
| E1 | 144 (56.3) | 2 (0.8) | <0.001 | 159.4 (38.8–655.1) | 170.6 (41.3–705.0) |
| NE2 | 104 (40.6) | 2 (0.8) | <0.001 | 84.8 (20.6–348.8) | 85.7 (20.7–354.2) |
| CE2 | 137 (53.5) | 2 (0.8) | <0.001 | 142.8 (34.7–586.5) | 157.5 (38.0–653.2) |
| NE2 and/or CE2a | 144 (56.3) | 2 (0.8) | <0.001 | 159.4 (38.8–655.1) | 177.5 (42.8–736.9) |
| E4 | 61 (23.8) | 3 (1.2) | <0.001 | 25.8 (8.0–83.3) | 26.9 (8.3–87.4) |
| E5 | 9 (3.5) | 2 (0.8) | 0.063 | 4.5 (1.0–21.1) | 4.7 (1.0–22.8) |
| E6 | 148 (57.8) | 3 (1.2) | <0.001 | 112.8 (35.2–361.8) | 130.6 (40.1–425.5) |
| E7 | 148 (57.8) | 3 (1.2) | <0.001 | 112.8 (35.2–361.8) | 147.4 (45.0–483.1) |
| E6 and/or E7a | 194 (75.8) | 6 (2.4) | <0.001 | 127.2 (53.9–300.4) | 241.4 (92.6–629.4) |
| NE2, CE2, E6, and/or E7a | 203 (79.3) | 7 (2.8) | <0.001 | 133.0 (59.2–298.9) | 249.1 (99.3–624.9) |
| Any Ea | 210 (82.0) | 10 (4.0) | <0.001 | 109.6 (53.9–222.5) | 243.7 (101.4–586.0) |
| L1 | 15 (5.9) | 4 (1.6) | 0.017 | 3.8 (1.3–11.7) | 4.0 (1.3–12.3) |
| L2 | 0 | 1 (0.4) | 0.494 | NC | NC |
| Any La | 15 (5.9) | 5 (6.3) | 0.038 | 3.0 (1.1–8.5) | 3.1 (1.1–8.8) |
| Any E and/or La | 210 (82.0) | 12 (4.8) | <0.001 | 90.5 (46.7–175.5) | 193.8 (85.0–441.5) |
a
Any positive vs. all negative
b
Fisher’s exact test
c
Adjusted for age, smoking, and alcohol status
NC, not calculable due to zero cells